I dont know why everybody is in such a rush to sell. There is quite a bit of trial data to come out in the next quarter. Malcolm has been on and on about the more data the valuable we are to the larger companies.
It comes down to the quality of the product. The buyers are in to make a profit, and in a market worth billions, if the product has a potential to make lots of money for them why would they want to walk away from massive profit just for spite. Mercks Keytruda revenue is US$4 billion PER YEAR, they are want to buy Viralytics for 10% of that.
I would love to buy a holiday house from some of you guys with my first (and final) offer.
VLA Price at posting:
$1.69 Sentiment: Buy Disclosure: Held
